This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Janssen Pharmaceutica Nv. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Katrien Luyten: Innovator in Prostate Cancer Treatment
Introduction
Katrien Luyten is a notable inventor based in Oud-Turnhout, Belgium. She has made significant contributions to the field of oncology, particularly in the treatment of prostate cancer. Her innovative approach combines established therapies to enhance treatment efficacy.
Latest Patents
Katrien Luyten holds 1 patent for her work titled "Treatment of prostate cancer with a combination of abiraterone acetate, niraparib tosylate monohydrate and prednisone." This patent discloses a combination of abiraterone acetate and niraparib, including both free-dose and fixed-dose combinations, aimed at improving treatment outcomes for prostate cancer patients.
Career Highlights
Katrien is associated with Janssen Pharmaceutica NV, a leading pharmaceutical company known for its commitment to innovative healthcare solutions. Her work at Janssen has positioned her as a key player in the development of new cancer therapies.
Collaborations
Throughout her career, Katrien has collaborated with esteemed colleagues such as Thomas Ronald A Quinten and Kaustubh Ramesh Tambwekar. These partnerships have fostered a collaborative environment that enhances research and development efforts in cancer treatment.
Conclusion
Katrien Luyten's contributions to prostate cancer treatment exemplify the impact of innovative thinking in medicine. Her patent and collaborative efforts reflect her dedication to improving patient outcomes through advanced therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile